Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing
Rafael (NYSE:RFL) reported top-line results from its pivotal Phase III TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C, a rare, progressive genetic disorder. The company said it remains on track to submit a New Drug Application to the U.S. Food and Dr
